People on the Move
Deciphera Pharmaceuticals
The clinical-stage biopharmaceutical company Deciphera has hired oncology expert Oliver Rosen as Chief Medical Officer. Deciphera’s pipeline involves improved kinase inhibitor treatments targeting the tumour microenvironment, and Rosen will take on its several clinical programmes.
The new Chief Medical Officer previously held clinical oncology positions at biotechnology companies including Millennium (part of Takeda), Genentech, Amgen, Hoffman La Roche and Merck KGaA. At Hoffman LaRoche, Rosen was responsible for Phase 3 Avastin programmes. He received his training in oncology and haematology at the University Hospital Charite in Berlin, with a focus on bone marrow transplantation.
Deciphera, based in Lawrence, Kansas, has a proprietary platform which it calls “an evolution” on traditional Type 2 kinase inhibitors, “by providing more robust and durable kinase binding in dysregulated oncogenic disease states.”
